血管緊張素受體拮抗劑聯(lián)合用藥治療高血壓患者的療效觀察

《血管緊張素受體拮抗劑聯(lián)合用藥治療高血壓患者的療效觀察》由會員上傳分享，免費在線閱讀，更多相關(guān)內(nèi)容在工程資料-天天文庫。

1、血管緊張素受體拮抗劑聯(lián)合用藥治療高血壓患者的療效觀江蘇省泰興市張橋衛(wèi)生院225400【摘要】目的觀察血管緊張素受體拮抗劑(ARB)聯(lián)合β受體阻滯劑治療高血壓患者的臨床療效。方法選擇泰興市張橋衛(wèi)生院全科門診自2012年3月至2015年3月期間就診的100例高血壓患者，隨機分為觀察組和對照組，每組50例。觀察組采用ARB聯(lián)合β受體阻滯劑即纈沙坦和美托洛爾緩釋片聯(lián)合治療；對照組采用鈣拮抗劑(CCB)聯(lián)合β受體阻滯劑即氨氯地平聯(lián)合美托洛爾緩釋片。觀察和比較兩組治療后10周的收縮壓、舒張壓和心率變化情況以及癥狀改善情況。結(jié)果治療10周后，兩組收

2、縮壓、舒張壓和心率均較治療前丁降顯著，差異有統(tǒng)計學(xué)意義(P<0.05);觀察組治療10周后收縮壓、舒張壓與對照組比較，差異無統(tǒng)計學(xué)意義(P>0.05)；但治療10周后心率和癥狀改善情況明顯優(yōu)于對照組，差異有統(tǒng)計學(xué)意義(P<0.05)。結(jié)論ARB聯(lián)合β受體阻滯劑治療高交感張力高血壓患者，具有安全有效、不良反應(yīng)少的優(yōu)點，值得臨床推廣，尤其是在基層。【關(guān)鍵詞】高血壓；血管緊張素受體拮抗劑；β受體阻滯劑；鈣拮抗劑；心率；收縮壓；舒張壓[Abstract]ObjectiveToobservetheclinicaleffectofangiotensinre

3、ceptorblockers(ARB)combinedwithbetablockersinthetreatmentofhypertension.Methods100patientswithhypertensionfromMarch2015toMarch2012wererandomlydividedintoobservationgroupandcontrolgroup,50casesineachgroup.TheobservationgroupwastreatedwithARBcombinedwithabetablockerorvalsartanandmetopro

4、lolsustained-releasetabletscombinedtreatment；controlgroupwithcalciumantagonists(CCB)combinedwithabetablockeroramlodipinecombinedwithmetoprololsustained-releasetablets.Thechangesofsystolicbloodpressure,diastolicbloodpressure，heartrateandtheimprovementofsymptomswereobservedandcomparedbe

5、tweenthetwogroupsafter10weeksoftreatment.ResultsAfter10weeksoftreatment,thesystolicbloodpressure,diastolicbloodpressureandheartrateofthetwogroupsweresignificantlylowerthanthosebeforetreatment,thedifferencewasstatisticallysignificant(P<0.05)；After10weeksoftreatment,thesystolicbloodp

6、ressureanddiastolicbloodpressureoftheobservationgroupwerecomparedwiththatofthecontrolgroup(P>0.05)；Butafter10weeksoftreatment，heartrateandsymptomimprovementweresignificantlybetterthanthecontrolgroup,thedifferencewasstatisticallysignificant(P<0.05).ConclusionARBcombinedwithbetabl

7、ockersinthetreatmentofpatientswithhighbloodpressureandhypertension，hastheadvantagesofsafeandeffective，lessadversereactions，itisworthyofclinicalpromotion,especiallyatthegrassrootslevel.【Keywords】Hypertension;Angiotensinreceptorblockers；Betablockers；Calciumantagonists；Heartrate；Systolic

8、blood